May 2019 No.19-01

IMPORTANT

Dear Healthcare Professionals Letter of Rapid Safety Communication BLUE LETTER

Serious Interstitial lung disease by Verzenio Tablets 50 mg, 100 mg, 150 mg.

Since their launch in Japan on November 30, 2018, 14 serious cases of interstitial lung disease have been reported in patients treated with Verzenio Tablets 50 mg, 100 mg, or 150 mg (hereinafter referred to as “this drug”) in Japan as of May 14, 2019 under the early post-marketing phase vigilance of the drug. Three of the 14 cases were reported as resulting in mortality (the estimated number of patients using this drug is approximately 2 000*). To address the situation, it has been decided that a Warning section should be newly added for a cautionary statement to the Precautions in the package insert for Health care professionals (hereinafter referred to as “HCP “) of this drug for alerting purpose.

*Estimated for a period from the start of marketing to May 14, 2019.

HCPs are requested to pay careful attention to the following points when using this drug.

- When administering this drug, patients should be carefully monitored for initial symptoms of interstitial lung disease (such as dyspnoea, cough, and pyrexia) and by performing a chest X-ray, etc.
- If any abnormalities are observed, administration of this drug should be discontinued and appropriate measures should be taken while performing a chest CT scan or serum marker test, etc. as necessary.
- Patients or their families should be instructed to immediately contact their physicians or pharmacists when they experience any initial symptoms of interstitial lung disease (such as dyspnoea, cough, and pyrexia).

Please note that the Warning, Important Precautions, and Clinically Significant Adverse Reactions sections have been revised.

Refer to Page 3 for contact information.

Revisions of Precautions in the Package Insert

Revised language is underlined. (____: by the instruction from MHLW, _____: voluntary revision by MAH , ~~____~~:deleted)

Revised	Current
Warnings 1. This drug should be administered in a medical institution sufficiently capable of responding to emergency situations, under physicians with adequate knowledge and experience of cancer therapy, and only to patients for whom administration of this drug is considered appropriate. In addition, patients or their families should be sufficiently informed of the effectiveness and risks of this drug and their consent should be obtained prior to administration. 2. Cases of interstitial lung disease resulting in mortality have been reported. Patients should be carefully monitored for initial symptoms (such as dyspnoea, cough, and pyrexia) and by performing a chest X-ray, etc. If any abnormalities are observed, administration of this drug should be discontinued and a chest CT scan or serum marker test, etc. should be performed as necessary and appropriate measures should be taken. (See Careful Administration, Important Precautions, Clinically Significant Adverse Reactions sections.)	**Warnings** This drug should be administered in a medical institution sufficiently capable of responding to emergency situations, under physicians with adequate knowledge and experience of cancer therapy, and only to patients for whom administration of this drug is considered appropriate. In addition, patients or their families should be sufficiently informed of the effectiveness and risks of this drug and their consent should be obtained prior to administration.
Precautions **1. Careful Administration (this drug should be administered with caution to the following patients)** (1) Patients with severe hepatic impairment (snip.) (2) Patients with interstitial lung disease or a history of the disease (Interstitial lung disease may be exacerbated. (See Warnings, Important Precautions, and Clinically Significant Adverse Reactions sections.)	**Precautions** **1. Careful Administration (this drug should be administered with caution to the following patients)** Patients with severe hepatic impairment (snip.)
2. Important Precautions (2) Interstitial lung disease may occur. When using this drug, patients should be carefully monitored for initial symptoms (such as dyspnoea, cough, and pyrexia) and by performing a chest X-ray, etc. A chest CT scan or serum marker test, etc. should be performed as necessary. Patients should be adequately informed of adverse reactions associated with this drug and instructed to immediately contact medical institutions when they experience any initial symptoms of the disease. (See Warnings, Important Precautions, and Clinically Significant Adverse Reactions sections.)	**2. Important Precautions** (2) Interstitial lung disease may occur. When using this drug, patients should be carefully monitored for initial symptoms (such as dyspnoea, cough, and pyrexia) and by performing a chest X-ray, etc. A chest CT scan or serum marker test, etc. should be performed as necessary.

4. Adverse Reactions	4. Adverse Reactions
(1) Clinically Significant Adverse Reactions 4) Interstitial lung disease (2.7%): Interstitial lung disease may occur. Patients should be carefully monitored. If any abnormalities are observed, this drug should be discontinued and a chest CT scan or serum marker test, etc. should be performed as necessary, and appropriate measures should be taken. (See the Warning, Careful Administration, and Important Precautions sections.)	(1) Clinically Significant Adverse Reactions 4) Interstitial lung disease (2.7%): Interstitial lung disease may occur. Patients should be carefully monitored. If any abnormalities are observed, appropriate measures should be taken such as discontinuing this drug.

For information for the proper use of this drug, please visit the web site below.

Eli Lilly Japan K.K. Product information portal site for healthcare professionals: www.lillymedical.jp (only in Japanese)

Marketing Authorization Holder: Eli Lilly Japan K.K.
Isogamidori 5-1-28,
Chuo-ku,
Kobe-shi, 651-0086

Contact Information

Eli Lilly Japan K.K. Medical Information Service

Toll-free: 0120－360－605

- **May 17, 2019 to May 31, 2019: 8:45-17:30 (7 days/week)**
- **June 6, 2019 and thereafter: 8:45-17:30 (not available on Saturday, Sunday, national and company's holidays)**